Cargando…

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

OBJECTIVES: Interventions aimed at increasing TNF-α inhibitor serum drug levels (SDLs) may improve treatment response; however, previous studies suggesting SDL cut-offs have not accounted for treatment adherence. The aim of this study was to establish the relationship between adalimumab/certolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hum, Ryan M, Ho, Pauline, Nair, Nisha, Jani, Meghna, Morgan, Ann W, Isaacs, John D, Wilson, Anthony G, Hyrich, Kimme L, Plant, Darren, Barton, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234202/ https://www.ncbi.nlm.nih.gov/pubmed/36190343 http://dx.doi.org/10.1093/rheumatology/keac564

Ejemplares similares

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
por: Jani, Meghna, et al.
Publicado: (2017)

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
por: Jani, Meghna, et al.
Publicado: (2016)

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis
por: Nair, Nisha, et al.
Publicado: (2020)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: OIiver, James, et al.
Publicado: (2021)

Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: Oliver, James, et al.
Publicado: (2021)

Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2019)

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score
por: Gilani, Syed SA, et al.
Publicado: (2020)

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, James, et al.
Publicado: (2015)

Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2016)

Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis
por: Smith, Samantha Louise, et al.
Publicado: (2023)

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
por: Maciejewski, Mateusz, et al.
Publicado: (2021)

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2017)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples
por: Smith, Samantha Louise, et al.
Publicado: (2015)

Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy
por: Sutcliffe, Megan, et al.
Publicado: (2022)

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients
por: Ling, Stephanie F., et al.
Publicado: (2019)

Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Plant, Darren, et al.
Publicado: (2012)

Previously reported PDE3A–SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2016)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

EULAR definition of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2021)

Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
por: Ramos, Guilherme Piovezani, et al.
Publicado: (2021)

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
por: Nagy, György, et al.
Publicado: (2022)

Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register
por: Humphreys, Jennifer H, et al.
Publicado: (2013)

Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate
por: Barton, Anne, et al.
Publicado: (2020)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Certolizumab in the long-term treatment of rheumatoid arthritis
por: Khan, Abdul, et al.
Publicado: (2011)

EP19 Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis: a case report
por: Hum, Ryan Malcolm, et al.
Publicado: (2020)

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, J, et al.
Publicado: (2014)

Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes
por: Hope, Holly F, et al.
Publicado: (2016)

Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment
por: Tan, Rachael J L, et al.
Publicado: (2010)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era
por: Morgan, Catharine, et al.
Publicado: (2015)

Development of a sensitive biochemical assay for the detection of tofacitinib adherence
por: Church, Stephanie, et al.
Publicado: (2023)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
por: Humphreys, Jenny, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rfdg16b8bgg112obgv29c4r9gd